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Abstract
Background: Malaria in pregnancy, including asymptomatic infection, has a detrimental impact on foetal
development. Individual patient data (IPD) meta-analysis was conducted to compare the association between
antimalarial treatments and adverse pregnancy outcomes, including placental malaria, accompanied with the
gestational age at diagnosis of uncomplicated falciparum malaria infection.
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Methods: A systematic review and one-stage IPD meta-analysis of studies assessing the efficacy of artemisinin-
based and quinine-based treatments for patent microscopic uncomplicated falciparum malaria infection (hereinafter
uncomplicated falciparum malaria) in pregnancy was conducted. The risks of stillbirth (pregnancy loss at ≥ 28.0
weeks of gestation), moderate to late preterm birth (PTB, live birth between 32.0 and < 37.0 weeks), small for
gestational age (SGA, birthweight of < 10th percentile), and placental malaria (defined as deposition of malaria
pigment in the placenta with or without parasites) after different treatments of uncomplicated falciparum malaria
were assessed by mixed-effects logistic regression, using artemether-lumefantrine, the most used antimalarial, as the
reference standard. Registration PROSPERO: CRD42018104013.
Results: Of the 22 eligible studies (n = 5015), IPD from16 studies were shared, representing 95.0% (n = 4765) of the
women enrolled in literature. Malaria treatment in this pooled analysis mostly occurred in the second (68.4%, 3064/
4501) or third trimester (31.6%, 1421/4501), with gestational age confirmed by ultrasound in 91.5% (4120/4503).
Quinine (n = 184) and five commonly used artemisinin-based combination therapies (ACTs) were included:
artemether-lumefantrine (n = 1087), artesunate-amodiaquine (n = 775), artesunate-mefloquine (n = 965), and
dihydroartemisinin-piperaquine (n = 837). The overall pooled proportion of stillbirth was 1.1% (84/4361), PTB 10.0%
(619/4131), SGA 32.3% (1007/3707), and placental malaria 80.1% (2543/3035), and there were no significant
differences of considered outcomes by ACT. Higher parasitaemia before treatment was associated with a higher risk
of SGA (adjusted odds ratio [aOR] 1.14 per 10-fold increase, 95% confidence interval [CI] 1.03 to 1.26, p = 0.009) and
deposition of malaria pigment in the placenta (aOR 1.67 per 10-fold increase, 95% CI 1.42 to 1.96, p < 0.001).
Conclusions: The risks of stillbirth, PTB, SGA, and placental malaria were not different between the commonly used
ACTs. The risk of SGA was high among pregnant women infected with falciparum malaria despite treatment with
highly effective drugs. Reduction of malaria-associated adverse birth outcomes requires effective prevention in
pregnant women.
Keywords: Falciparum malaria, Pregnancy, Treatment, Safety, Stillbirth, Small for gestational age, Preterm birth,
Systematic review, Artemisinin, Quinine
Background
Malaria during pregnancy has adverse impacts on the
foetus including increased risks of pregnancy loss (i.e.
miscarriage or stillbirth) [1, 2], preterm birth (PTB) [3,
4], intrauterine growth restriction (IUGR), and small for
gestational age (SGA) [3, 5, 6]. PTB is the major reason
for neonatal and infant mortality globally, and the high-
est burden of mortality occurs in low- and middle-
income countries, where malaria is endemic [7]. IUGR
leads to a higher risk of stillbirth [8] and is associated
with increased short-term mortality and morbidity [7].
SGA is a proxy for IUGR, and risk extends beyond in-
fancy as they are associated with a higher risk of meta-
bolic disorders, and possibly mental disorders or
cognitive impairment in later adult life [9, 10].
The most widely reported adverse impact of malaria in
pregnancy is low birthweight (LBW), commonly defined
as birthweight less than 2500 g and used as a proxy for
foetal growth [11, 12]. However, LBW does not distin-
guish between being “born to early” (or PTB) or “born
to small” (or IUGR), or both, which are associated with
different neonatal mortality and morbidity. For the pur-
pose of summarizing international evidence, LBW is a
poor proxy as newborns in Asia are generally smaller
than Africa [13], and gestational age distribution can
also vary between different regions [14]. A better proxy
for IUGR is SGA, defined as < 10th percentile of the
standard growth chart, which takes account of sex and
gestational age. An advance in the last decade is that an
international standard foetal growth chart defining SGA
has become available [15] permitting standardized com-
parison using SGA to summarize the evidence of the im-
pact of malaria on foetal growth.
Placental malaria (i.e. sequestration of malaria para-
sites in the placenta) is one of the primary pathogenic
mechanisms by which malaria during pregnancy can
cause adverse effects to the foetus [16, 17]. Many studies
have been conducted to assess the relationship between
placental malaria and adverse pregnancy outcomes and
have confirmed the association [18–20]. Placental mal-
aria is a direct consequence of malaria infection and is
therefore an efficacy outcome measure after treatment
or intermittent preventive treatment in pregnancy
(IPTp) [21, 22].
Artemisinin-based combination therapies (ACTs) are
highly effective with expected ≥ 95% treatment success
(clearance of peripheral parasitaemia) in pregnancy [23,
24]. However, few studies have been powered to specific-
ally explore the impact of different treatments on ad-
verse pregnancy outcomes and placental malaria.
In this study, individual patient data (IPD) from treat-
ment efficacy studies have been pooled to describe the
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risks of adverse pregnancy outcomes (i.e. indirect conse-
quences) and placental malaria (i.e. a direct consequence)
after the treatment of uncomplicated falciparum malaria
during pregnancy accompanied with reliable gestational
age, mostly estimated by ultrasound, at the times of diag-
nosis of uncomplicated falciparum malaria infection and
delivery. This study aims to compare the risks of stillbirth,
PTB, SGA, and placental malaria after different treatments
for patent microscopic falciparum malaria (uncomplicated
or asymptomatic) mainly in the second and third trimes-
ter, using artemether-lumefantrine (AL), the most used
ACT, as the reference standard.
Methods
Search strategy and inclusion criteria
A systematic review and IPD meta-analysis on the efficacy
of artemisinin-based and quinine-based treatments on un-
complicated falciparum malaria in pregnancy was conducted
with registration to PROSPERO (CRD42018104013). Briefly,
a combination of five components were searched in seven
databases (Medline, Embase, Global Health, Cochrane Li-
brary, Scopus, Web of Science, and Literatura Latino Ameri-
cana em Ciências da Saúde) and two clinical trial registries
(International Clinical Trials Registry Platform and Clinical-
Trials.gov) on 26 April 2019 without any restrictions on lan-
guage or publication year: malaria, pregnancy, treatment or
names of antimalarial drugs, study design (interventional or
observational cohort studies), and outcome types (efficacy).
Studies were included if Plasmodium falciparum para-
sitaemia was confirmed by microscopy before treat-
ment, the length of active follow-up was ≥ 28 days,
polymerase chain reaction (PCR) was used to classify
recurrence of falciparum malaria, gestational age at
detection of parasitaemia and delivery was verified,
and pregnant women were followed up until delivery
for assessing pregnancy outcomes. Investigators were in-
vited to join this project and share the IPD with the
WorldWide Antimalarial Resistance Network (WWARN),
which were then standardized for the IPD meta-analysis
as described in the published protocol [25].
Definition of outcomes
Miscarriage was defined as foetal death before 28.0
weeks of gestation, and stillbirth was defined as foetal
death before birth resulting in delivery of a newborn
with no signs of life at ≥ 28.0 weeks of gestation (regard-
less of birthweight) [26, 27]. PTB was defined as birth of
a live infant before 37.0 weeks of gestation [28]: ex-
tremely PTB (< 28.0 weeks), very PTB (≥ 28.0 to < 32.0
weeks), and moderate to late PTB (≥ 32.0 to < 37.0
weeks) [29]. SGA was defined as birthweight lower than
the 10th percentile [30, 31] of the INTERGROWTH-
21st international standard growth chart [15].
Placental histopathology was categorized according to
the malaria parasites and malaria pigment as follows
[32]: no infection (both parasites and pigment are nega-
tive), acute infection (only parasites are present), past in-
fection (only pigment present), and chronic infection
(both parasites and pigment are present). The presence
of malaria pigment (i.e. both past and chronic infections)
was analysed in order to assess the effect of malaria in-
fection during pregnancy prior to labour as the presence
of parasites in the placenta is more closely associated
with acute parasitaemia at delivery than parasitaemia
earlier in pregnancy [16].
Inclusion criteria at the individual level
Only singleton births without congenital abnormality
were analysed, except for calculating the proportion of
congenital abnormality, which included all pregnant
women with delivery information. The proportion of
miscarriage was calculated excluding malaria episodes at
≥ 28.0 weeks of gestation. PTB included only live single-
ton births and excluded pregnant women who had the
first recorded malaria at ≥ 28.0 weeks of gestation (for
extremely PTB), ≥ 32.0 (for very PTB), or ≥ 37.0 (for
moderate to late PTB). Only live singleton births deliv-
ered < 43.0 weeks of gestation were included for asses-
sing SGA. Newborns whose birthweight was assessed
within 3 days were included in the birthweight analyses.
Statistical analysis
All statistical analyses were performed using R (version
3.2.5, R Foundation for Statistical Computing, Vienna,
Austria) or Stata MP 15.1 (StataCorp, College Station,
TX, USA). One-stage IPD meta-analysis was conducted:
univariable and multivariable mixed-effects logistic re-
gression models were used to model risk of (i) stillbirth,
(ii) PTB, (iii) SGA, and (iv) placental malaria. Study site
was fitted as a random intercept in these models. Het-
erogeneity between studies was assessed by intraclass
correlation. Multiple imputation (MI) was used for
handling missing values of covariates to test the effect of
exclusion of patients with missing data on our main con-
clusions. For the key analysis, both MI (presented as the
main model) and complete case analyses are presented.
MI was conducted in Stata MP 15.1 with 20 imputations
using mi impute mvn command to impute missing
values of HIV status (~ 18% missing) and height (~ 14%
missing). As recommended when MI is used, the Wald
test was used for model building [33, 34] by backward
elimination using p < 0.05 as the cut-off (see MI proced-
ure in Additional file 1). Treatment was always included
in the model regardless of its significance using AL,
which is the most used ACT, as the reference. Compari-
sons of each pair of drugs were not conducted to avoid
multiple testing. HIV status was always adjusted as a
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confounder except in analysis of placental malaria [35].
For placental malaria, malaria transmission intensity was
included in the multivariable model as an a priori con-
founder, and interaction between parity and malaria
transmission was assessed because pregnancy-specific
(parity-dependent) immunity can be different depending
on malaria transmission intensity. If the number of over-
all observations (or outcomes) was small, multivariable
analysis was not attempted and only univariable mixed-
effects logistic regression (by treatment) or pooled propor-
tions with 95% confidence interval (CI) taking account for
study site (pooled by DerSimonian and Laird’s random ef-
fects after Freeman-Tukey double arcsine transformation)
were presented [36]. Raw numbers were presented for ref-
erences, but these fractions were not necessarily the same
as the shown proportions, which were pooled by random
effects. Risk of bias assessment is available in Add-
itional file 2. Two post hoc sensitivity analyses (one re-
garding gestational age and the other stratified by
geographical region) were conducted (Additional file 3).
As the majority of the studies included second (≥ 14.0
to < 28.0 weeks) or third trimester (≥ 28.0 weeks) women,
the gestational period between ≥ 14.0 and < 37.0 weeks
was divided into four periods that had a similar number
of women, and women included for a malaria episode
before 14.0 weeks and after 37.0 weeks constituted a
fifth and a sixth group, respectively. Gravidity (G) and
previous history of pregnancy loss were jointly catego-
rized (G1, G2 with no loss, G ≥ 3 with no loss, G2 with 1
loss, G ≥ 3 with 1 loss, and G ≥ 3 with ≥ 2 losses) and al-
ways adjusted in the multivariable analyses as a con-
founder for assessing stillbirth, PTB, and SGA [8, 35].
Previous history of pregnancy loss was estimated by
(enrolement gravidity – parity − 1), with a lower limit of
0. Age was categorized as < 20, 20–24, 25–29, 30–34,
and ≥ 35 years [37].
Results
Study inclusion
Of the 28 identified studies in the literature with PCR-
corrected efficacy, 22 studies assessed pregnancy out-
comes, resulting in a total of 5015 women enrolled in
those trials. Data of 4765 women from 16 studies, repre-
senting 95.0% of the total target, were shared to the
WWARN repository and pooled for this IPD meta-
analysis. Delivery information was available for 4503
women (3607 in Africa and 896 in Asia) and missing for
5.5% (262/4765) including 256 lost to follow-up and six
maternal deaths. Of the 4501 women with estimated
gestational age, 68.1% (3064/4501) had documented
falciparum malaria in the second trimester and 31.6%
(1421/4501) in the third trimester. Only 16 malaria
episodes (0.3%, 16/4501) were reported in the first tri-
mester. After excluding twin pregnancies (1.4%, 63/
4503), 4440 women with singleton deliveries were
included (Fig. 1).
Ultrasound was used to estimate gestational age in
eight studies (Additional Table 1), comprising 91.5%
(4120/4503) of the women. One study did not have in-
formation on gestational age. Another study assessed
EGA by ultrasound but reported EGA only in weeks (de-
tails are available in Additional file 3).
Histopathology of the placenta was assessed in 3128
pregnant women in six studies with PCR-corrected effi-
cacy in the literature, and IPD of 3033 women (97.0%)
in four studies were shared and analysed.
Congenital abnormality
The overall proportion of congenital abnormality pooled
by DerSimonian and Laird’s random effects was 0.4%
(58/4440, 95% CI 0.1 to 0.9, I2 39%). However, congeni-
tal abnormalities were only reported in live born infants
(n = 4335). As they are a known contributor to stillbirths,
congenital abnormalities were likely to be underesti-
mated. There was no difference among different treat-
ments (p = 0.68). No further analyses were conducted
because of the small number of cases. The 58 pregnan-
cies with congenital abnormality were excluded from the
analyses that follow.
Miscarriage
The overall pooled proportion of miscarriage was 0.0%
(21/2932, 95% CI 0.0 to 0.1, I2 0%, Additional Figure 1)
among 2932 pregnant women who had malaria < 28.0
weeks of gestation (mean 21.4, standard deviation 3.5
weeks) and were followed up to the end of pregnancy.
There was no difference among different treatments
(p = 0.60). No further analyses were conducted because
of the small number of cases.
Stillbirth
The overall pooled proportion of stillbirth was 1.1% (84/
4361, 95% CI 0.6 to 1.7, I2 29%, Additional Figure 2),
among pregnant women who were followed up until de-
livery, excluding those who had a miscarriage. Pregnant
women for whom there was no information on EGA
(n = 27) were excluded from the subsequent analysis on
stillbirth.
Of the 4334 women, nine antimalarial treatments were
used and included in the analyses on stillbirth: AL
(n = 1087), artesunate-amodiaquine (ASAQ, n = 775),
artesunate-mefloquine (ASMQ, n = 965), dihydroartem
isinin-piperaquine (DP, n = 837), artesunate-sulfadoxi
ne-pyrimethamine (ASSP, n = 154), artesunate mono-
therapy (AS, n = 193), artesunate-atovaquone-proguanil
(AAP, n = 81), quinine monotherapy (n = 184), and quin-
ine with clindamycin (QC, n = 58) (Table 1).
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The median age was 22 (interquartile range 19–27),
and gravidity was 2 (interquartile range 1–4). Malaria
episodes in the included studies were mostly in the sec-
ond (68.0%, 2949/4334) or third trimester (31.6%, 1371/
4334). The majority of the episodes (99.3%, 4302/4334)
were P. falciparum mono-infections (Table 1). A small
proportion (35/3019 assessed) were HIV positive, and
these women had not received antiretroviral treatment
during pregnancy. Only eight women received
cotrimoxazole prophylaxis. HIV results were unavail-
able for 643 women enrolled in nine studies con-
ducted on the Thailand-Myanmar border, where the
seroprevalence of HIV is < 0.5% [38]. They were thus
regarded as HIV negative in the following analyses.
In both the univariable and multivariable analyses, dif-
ferent antimalarial treatments were not associated with
different risk of stillbirth using AL as the reference
(Table 2). In the multivariable analysis adjusted for HIV
status and gravidity combined with a previous history of
pregnancy loss, the risk of stillbirth was higher in
women with HIV infection (adjusted odds ratio [aOR]
4.35, 95% CI 1.15 to 16.52, p = 0.03) and lower in multi-
gravid women who had no previous pregnancy loss
(aOR 0.51, 95% CI 0.27 to 0.97, p = 0.04) compared with
Fig. 1 Flowchart of eligible studies included in the analysis
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Table 2 Univariable and multivariable logistic regression on the risk of stillbirth
Baseline characteristic Proportion
(%)
Univariable Multivariable (complete case) Multivariable (MI)
OR (95% CI) p value aOR (95% CI) p value aOR (95% CI) p value
Treatment
AL 19/1087 (2%) Reference Reference Reference
AAP 1/81 (1%) 0.61 (0.08–4.93) 0.64 0.99 (0.13–7.67) 0.99 0.82 (0.10–6.46) 0.85
AS 2/193 (1%) 0.56 (0.12–2.57) 0.45 0.80 (0.18–3.61) 0.77 0.67 (0.15–3.02) 0.60
ASAQ 13/775 (2%) 0.89 (0.42–1.88) 0.76 0.96 (0.40–2.32) 0.93 1.00 (0.47–2.10) 0.99
ASMQ 23/965 (2%) 1.20 (0.62–2.32) 0.58 1.58 (0.76–3.25) 0.22 1.38 (0.70–2.70) 0.35
ASSP 4/154 (3%) 1.43 (0.42–4.81) 0.57 1.23 (0.34–4.49) 0.75 1.35 (0.42–4.41) 0.62
DP 19/837 (2%) 1.09 (0.54–2.18) 0.81 1.36 (0.65–2.85) 0.41 1.22 (0.60–2.47) 0.58
Q 2/184 (1%) 0.51 (0.11–2.34) 0.39 0.71 (0.16–3.25) 0.66 0.51 (0.11–2.33) 0.39
QC 1/58 (2%) 0.81 (0.09–7.15) 0.85 1.40 (0.18–11.01) 0.75 1.12 (0.14–9.24) 0.92
EGA at malaria episode
4.0–13.9 0/38 (0%) No data
14.0–19.9 22/896 (2%) Reference
20.0–23.9 20/1065 (2%) 0.72 (0.39–1.33) 0.30
24.0–27.9 21/964 (2%) 0.82 (0.45–1.51) 0.53
28.0–36.9 19/1319 (1%) 0.51 (0.27–0.95) 0.04
≥ 37.0 (weeks) 2/51 (4%) 1.63 (0.37–7.32) 0.52
Age group
< 20 27/1388 (2%) Reference
20–25 27/1399 (2%) 0.97 (0.56–1.66) 0.91
25–30 18/836 (2%) 1.10 (0.60–2.02) 0.76
30–35 6/419 (1%) 0.73 (0.30–1.77) 0.48
≥ 35 (years) 6/292 (2%) 1.03 (0.42–2.54) 0.95
Pregnancy history
G1 33/1519 (2%) Reference Reference Reference
G2 with no loss 11/741 (1%) 0.68 (0.34–1.35) 0.27 0.52 (0.23–1.15) 0.11 0.63 (0.31–1.26) 0.19
G≥ 3 with no loss 15/1165 (1%) 0.60 (0.33–1.11) 0.11 0.47 (0.23–0.98) 0.04 0.51 (0.27–0.97) 0.04
G2 with 1 loss 8/264 (3%) 1.28 (0.57–2.84) 0.55 1.12 (0.46–2.74) 0.81 1.35 (0.60–3.01) 0.47
G≥ 3 with 1 loss 11/462 (2%) 1.05 (0.53–2.11) 0.89 0.60 (0.25–1.49) 0.27 0.95 (0.46–1.93) 0.88
G≥ 3 with ≥ 2 losses 5/145 (3%) 1.45 (0.55–3.81) 0.45 0.98 (0.28–3.37) 0.97 1.33 (0.49–3.64) 0.58
Weight (kg) 84/4334 (2%) 1.01 (0.99–1.04) 0.34
Height (cm) 73/3809 (2%) 0.99 (0.95–1.02) 0.42
BMI (kg/m2)
< 18.5 8/239 (3%) 2.16 (1.01–4.62) 0.048
18.5–24.9 49/3044 (2%) Reference
25.0–29.9 12/458 (3%) 1.40 (0.71–2.77) 0.33
≥ 30.0 4/68 (6%) 2.86 (0.93–8.80) 0.07
HIV infection
Yes 3/35 (9%) 5.41 (1.57–18.65) 0.008 6.06 (1.69–21.68) 0.006 4.35 (1.15–16.52) 0.03
No 61/3627 (2%) Reference Reference Reference
Parasitaemia (log10/μL) 84/4334 (2%) 1.16 (0.90–1.51) 0.26
Fever > 37.5 °C
Yes 8/395 (2%) 1.20 (0.56–2.56) 0.64
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primigravidae. Higher haemoglobin on day 0 of the mal-
aria episode was associated with a higher risk of stillbirth
in the multiple imputation model, but not in the univari-
able and complete case multivariable model.
Preterm birth
The overall pooled proportions of extremely PTB
(< 28.0 weeks), very PTB (≥ 28.0 to < 32.0 weeks),
and moderate to late PTB (≥ 32.0 to < 37.0 weeks)
were 0.0% (8/2488, 95% CI 0.0 to 0.0, I2 0%), 0.4%
(47/3131, 95% CI 0.1 to 0.9, I2 11%), and 10.0%
(619/4131, 95% CI 7.0 to 13.4, I2 88%, Additional
Figure 3), respectively. Since the number of out-
comes of extremely PTB and very PTB was small
even when pooled, they were not analysed further.
The risk of moderate to late PTB among different
treatments used in five different pregnancy periods
was investigated.
The same nine antimalarial treatments were included
in this analysis: AL (n = 1035), ASAQ (n = 747), ASMQ
(n = 926), DP (n = 804), ASSP (n = 147), AS (n = 174),
AAP (n = 76), quinine (n = 171), and QC (n = 51). Base-
line characteristics (Additional Table 2) were similar to
that of pregnant women included in the analysis of still-
birth. The gestational period of pregnancy at the time of
malaria episode was divided into < 14.0 weeks (n = 38),
14.0–19.9 weeks (n = 863), 20.0–23.9 weeks (n = 1023),
24.0–27.9 weeks (n = 917), and 28.0–36.9 weeks (n =
1290).
In both the univariable and multivariable analyses, dif-
ferent antimalarial treatments were not associated with
moderate to late PTB in comparison with AL (Table 3).
Malaria between 14.0 and < 20.0 weeks was associated
with the lowest risk of PTB and was used as the refer-
ence. Malaria in the first trimester was associated with a
higher risk of PTB (aOR 3.92, 95% CI 1.38 to 11.13, p =
0.01). For each Isuccessive gestational period between
14.0 and < 37.0 weeks, the risk of PTB increased. Taller
maternal height (aOR 0.98 per cm, 95% CI 0.96 to 0.99,
p = 0.01) and higher maternal BMI (aOR 0.94 per kg/m2,
95% CI 0.90 to 0.97, p < 0.001) were linearly associated
with a lower risk of PTB. Teenagers and primigravidae
were independently associated with a higher risk of PTB.
Compared with primigravidae, the risk of PTB was lower
in G2 women with no previous pregnancy loss (aOR
0.65, 95% CI 0.48 to 0.89, p = 0.007) and G ≥ 3 women
with no loss (aOR 0.67, 95% CI 0.47 to 0.96, p = 0.03) or
one loss (aOR 0.66, 95% CI 0.44 to 0.99, p = 0.05). Com-
pared with women < 20 years old, the risk of PTB was
lower in 20–24 year olds (aOR 0.67, 95% CI 0.51 to 0.87,
p = 0.003), but not different in 25 and older. Compared
with moderate malaria transmission areas, the risk of
PTB was lower in low transmission areas but not differ-
ent in high transmission areas. When only studies in
sub-Saharan Africa were included (sensitivity analysis),
the risk of PTB was higher after ASSP than AL (aOR
4.90, 95% CI 1.23 to 19.48, p = 0.02) (Additional file 3).
Small for gestational age
Among 4277 live singleton births without congenital ab-
normality, 3707 births were considered in the analysis
after excluding 570 births for which SGA was not
assessed (248 without birthweight, 253 birthweight mea-
sured > 3 days after delivery, one without information on
sex of the baby, 41 born after 43.0 weeks, 27 without
EGA at delivery). The overall pooled proportion of SGA
Table 2 Univariable and multivariable logistic regression on the risk of stillbirth (Continued)
Baseline characteristic Proportion
(%)
Univariable Multivariable (complete case) Multivariable (MI)
OR (95% CI) p value aOR (95% CI) p value aOR (95% CI) p value
No 73/3897 (2%) Reference
Haemoglobin (g/dL) 84/4334 (2%) 1.13 (0.97–1.32) 0.12 1.14 (0.94–1.37) 0.18 1.20 (1.02–1.41) 0.03
Gametocytaemia
Yes 2/161 (1%) 0.67 (0.17–2.75) 0.58
No 79/4110 (2%) Reference
Mixed infection
Yes 0/32 (0%) No data
No 84/4302 (2%) Reference
Malaria transmission
Low 12/993 (1%) 0.44 (0.21–0.90) 0.03
Moderate 57/2348 (2%) Reference
High 15/993 (2%) 0.61 (0.30–1.26) 0.18
Intraclass correlation, < 0.01. AAP artesunate with atovaquone-proguanil, AL artemether-lumefantrine, aOR adjusted odds ratio, AS artesunate monotherapy, ASAQ
artesunate-amodiaquine, ASMQ artesunate-mefloquine, ASSP artesunate-sulfadoxine-pyrimethamine, BMI body mass index, CI confidence interval, DP
dihydroartemisinin-piperaquine, EGA estimated gestational age, G gravidity, HIV human immunodeficiency virus, MI multiple imputation, OR odds ratio, Q quinine
monotherapy, QC quinine with clindamycin
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Table 3 Univariable and multivariable logistic regression on the risk of moderate-to-late preterm birth
Baseline characteristic Proportion (%) Univariable Multivariable (complete case) Multivariable (MI)
OR (95% CI) p value aOR (95% CI) p value aOR (95% CI) p value
Treatment
AL 156/1035 (15%) Reference Reference Reference
AAP 4/76 (5%) 0.51 (0.15–1.70) 0.27 2.72 (0.50–14.75) 0.25 0.69 (0.19–2.44) 0.56
AS 15/174 (9%) 1.41 (0.63–3.18) 0.40 2.01 (0.74–5.47) 0.17 1.49 (0.64–3.50) 0.36
ASAQ 124/747 (17%) 1.04 (0.79–1.38) 0.76 1.03 (0.75–1.41) 0.88 1.05 (0.79–1.39) 0.75
ASMQ 128/926 (14%) 1.10 (0.84–1.46) 0.48 0.94 (0.68–1.30) 0.71 1.07 (0.80–1.41) 0.65
ASSP 22/147 (15%) 1.78 (0.87–3.63) 0.11 1.24 (0.50–3.09) 0.64 1.83 (0.88–3.81) 0.10
DP 151/804 (19%) 1.28 (0.98–1.66) 0.07 1.23 (0.93–1.64) 0.15 1.22 (0.93–1.60) 0.15
Q 15/171 (9%) 1.17 (0.57–2.40) 0.68 3.86 (0.92–16.19) 0.07 1.67 (0.79–3.54) 0.18
QC 4/51 (8%) 1.03 (0.26–4.08) 0.96 No data 1.39 (0.34–5.67) 0.65
EGA at malaria episode
4.0–13.9 5/38 (13%) 3.92 (1.42–10.87) 0.009 2.67 (0.73–9.80) 0.14 3.92 (1.38–11.13) 0.01
14.0–19.9 78/863 (9%) Reference Reference Reference
20.0–23.9 136/1023 (13%) 1.69 (1.25–2.28) < 0.001 1.63 (1.17–2.28) 0.004 1.71 (1.25–2.32) < 0.001
24.0–27.9 142/917 (15%) 2.17 (1.60–2.94) < 0.001 2.30 (1.64–3.24) < 0.001 2.37 (1.74–3.23) < 0.001
28.0–36.9 (weeks) 258/1290 (20%) 3.63 (2.72–4.85) < 0.001 4.49 (3.23–6.25) < 0.001 4.33 (3.21–5.84) < 0.001
Age group
< 20 284/1323 (21%) Reference Reference Reference
20–25 154/1330 (12%) 0.55 (0.44–0.68) < 0.001 0.69 (0.51–0.93) 0.02 0.67 (0.51–0.87) 0.003
25–30 100/803 (12%) 0.60 (0.47–0.78) < 0.001 1.01 (0.67–1.54) 0.96 0.82 (0.56–1.18) 0.29
30–35 46/401 (11%) 0.54 (0.38–0.76) < 0.001 0.78 (0.47–1.31) 0.34 0.72 (0.45–1.12) 0.15
≥ 35 (years) 35/274 (13%) 0.75 (0.51–1.11) 0.15 0.87 (0.47–1.62) 0.67 0.99 (0.60–1.64) 0.98
Pregnancy history
G1 284/1439 (20%) Reference Reference Reference
G2 with no loss 81/704 (12%) 0.56 (0.43–0.73) < 0.001 0.68 (0.48–0.96) 0.03 0.65 (0.48–0.89) 0.007
G≥ 3 with no loss 141/1128 (12%) 0.60 (0.48–0.75) < 0.001 0.59 (0.40–0.89) 0.01 0.67 (0.47–0.96) 0.03
G2 with 1 loss 41/251 (16%) 0.85 (0.59–1.24) 0.40 1.12 (0.75–1.68) 0.58 0.95 (0.65–1.40) 0.81
G≥ 3 with 1 loss 51/435 (12%) 0.60 (0.43–0.83) 0.002 0.69 (0.44–1.08) 0.10 0.66 (0.44–0.99) 0.046
G≥ 3 with ≥ 2 losses 18/137 (13%) 0.94 (0.55–1.58) 0.80 1.20 (0.62–2.32) 0.58 1.00 (0.56–1.79) 1.00
Weight (kg) 618/4130 (15%) 0.98 (0.97–0.99) 0.004
Height (cm) 579/3655 (16%) 0.99 (0.97–1.00) 0.05 0.98 (0.96–1.00) 0.01 0.98 (0.96–0.99) 0.01
BMI (kg/m2) 579/3655 (16%) 0.96 (0.93–1.00) 0.03 0.95 (0.91–0.99) 0.01 0.94 (0.90–0.97) < 0.001
HIV infection
Yes 4/31 (13%) 1.57 (0.51–4.73) 0.44 1.88 (0.35–10.15) 0.46 1.22 (0.36–4.09) 0.75
No 527/3462 (15%) Reference Reference Reference
Parasitaemia (log10/μL) 619/4131 (15%) 1.11 (0.99–1.24) 0.07
Fever > 37.5 °C
Yes 45/375 (12%) 1.09 (0.77–1.54) 0.62
No 563/3719 (15%) Reference
Haemoglobin (g/dL) 616/4107 (15%) 0.94 (0.88–1.00) 0.04
Gametocytaemia
Yes 24/153 (16%) 1.46 (0.92–2.32) 0.11
No 584/3922 (15%) Reference
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was 32.3% (1007/3707, 95% CI 26.7 to 38.2, I2 90%, Add-
itional Figure 4).
Antimalarial treatments included were AL (n = 973),
ASAQ (n = 700), ASMQ (n = 820), DP (n = 716), ASSP
(n = 129), AS (n = 154), AAP (n = 55), quinine (n = 119),
and QC (n = 41). Baseline characteristics (Additional
Table 3) were similar to pregnant women who were in-
cluded in the previous analysis of stillbirth and PTB.
In both univariable and multivariable analyses, differ-
ent antimalarial treatments were not statistically associ-
ated with SGA when compared with AL (Table 4). For
each successive gestational period between 14.0 and
< 37.0 weeks, the risk of SGA decreased, with a sig-
nificantly lower risk of SGA in women with malaria
treated between 28.0 and < 37.0 weeks of gestation.
Taller maternal height (aOR 0.95 per cm, 95% CI
0.93 to 0.96, p < 0.001) and higher maternal BMI
(aOR 0.92 per kg/m2, 95% CI 0.89 to 0.95, p < 0.001)
were associated with a lower risk of SGA. Higher
baseline parasitaemia (aOR 1.14 per 10-fold increase,
95% CI 1.03 to 1.26, p = 0.009) and co-infection of
other malaria species (aOR 2.54, 95% CI 1.07 to 5.99,
p = 0.03) were associated with a higher risk of SGA.
Compared with primigravidae, the risk of SGA was
lower in G2 women with no previous pregnancy loss
(aOR 0.62, 95% CI 0.49 to 0.78, p < 0.001) and G ≥ 3
women with no loss (aOR 0.48, 95% CI 0.39 to 0.60,
p < 0.001) or one loss (aOR 0.54, 95% CI 0.41 to 0.72,
p < 0.001).
Placental malaria
Among 3033 women in four studies that assessed pla-
cental histopathology, 441 (pooled prevalence 17.6%,
95% CI 12.1 to 23.8, I2 94%) women were categorized as
no infection, 49 (1.6%, 95% CI 0.8 to 2.5, I2 60%) acute
infection, 1816 (57.5%, 95% CI 53.6 to 61.5, I2 77%) past
infection, and 727 (21.6%, 95% CI 15.9 to 27.8, I2 93%)
chronic infection. Overall pooled positivity of malaria
pigment was 80.1% (2543/3033, 95% CI 73.5 to 85.9, I2
84%). The risk factors for deposition of malaria pigment
(i.e. past and chronic infection) were investigated in
2987 women.
Six antimalarial treatments were included in this ana-
lysis: AL (n = 893), ASAQ (n = 649), ASMQ (n = 668),
DP (n = 658), AS (n = 85), and quinine (n = 80). Baseline
characteristics (Additional Table 4) were similar to preg-
nant women who were included in the previous
analyses.
In both the univariable and multivariable analyses, the
risk of malaria pigment in the placenta did not differ be-
tween AL and the other treatments (Table 5). In the
multivariable analysis, shorter interval from malaria epi-
sode to delivery (aOR 0.97 per week, 95% CI 0.95 to
0.99, p = 0.002), lower age (aOR 0.93 per year, 95% CI
0.91 to 0.95, p < 0.001), higher body temperature (aOR
1.22 per °C, 95% CI 1.00 to 1.49, p = 0.05), lower haemo-
globin level (aOR 0.72 per g/dL, 95% CI 0.65 to 0.78,
p < 0.001), higher baseline parasitaemia (aOR 1.67 per
10-fold increase, 95% CI 1.42 to 1.96, p < 0.001), and
gametocytaemia before treatment (aOR 3.62, 95% CI
1.58 to 8.26, p = 0.002) were associated with a higher risk
of the presence of malaria pigment in the placenta.
When the effect of parity was analysed by different mal-
aria transmission intensities, the adjusted risk of placen-
tal malaria in pregnant women with ≥ 2 parities was
lower than nulliparous women in moderate (aOR 0.52,
95% CI 0.34 to 0.80, p = 0.003) and high (aOR 0.50, 95%
CI 0.26 to 0.98, p = 0.04) transmission areas, but not in
low transmission areas (aOR 1.26, 95% CI 0.62 to 2.59,
p = 0.53) (Additional Table 5).
Discussion
This IPD meta-analysis demonstrated that among the
four commonly used ACTs, namely AL, ASAQ, ASMQ,
and DP, the adjusted risks of stillbirth, PTB, SGA, and
past or chronic placental malaria (deposition of malaria
Table 3 Univariable and multivariable logistic regression on the risk of moderate-to-late preterm birth (Continued)
Baseline characteristic Proportion (%) Univariable Multivariable (complete case) Multivariable (MI)
OR (95% CI) p value aOR (95% CI) p value aOR (95% CI) p value
Mixed infection
Yes 2/29 (7%) 1.04 (0.24–4.52) 0.96
No 617/4102 (15%) Reference
Malaria transmission
Low 72/929 (8%) 0.55 (0.33–0.94) 0.03 0.24 (0.10–0.56) 0.001 0.42 (0.22–0.81) 0.009
Moderate 397/2236 (18%) Reference Reference Reference
High 150/966 (16%) 0.93 (0.54–1.62) 0.80 0.56 (0.28–1.09) 0.09 0.86 (0.47–1.58) 0.63
Intraclass correlation, 0.07. AAP artesunate with atovaquone-proguanil, AL artemether-lumefantrine, aOR adjusted odds ratio, AS artesunate monotherapy, ASAQ
artesunate-amodiaquine, ASMQ artesunate-mefloquine, ASSP artesunate-sulfadoxine-pyrimethamine, BMI body mass index, CI confidence interval, DP
dihydroartemisinin-piperaquine, EGA estimated gestational age, G gravidity, HIV human immunodeficiency virus, MI multiple imputation, OR odds ratio, Q quinine
monotherapy, QC quinine with clindamycin
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Table 4 Univariable and multivariable logistic regression on the risk of small for gestational age
Baseline characteristic Proportion (%) Univariable Multivariable (complete case) Multivariable (MI)
OR (95% CI) p value aOR (95% CI) p value aOR (95% CI) p value
Treatment
AL 241/973 (25%) Reference Reference Reference
AAP 25/55 (45%) 1.99 (0.89–4.45) 0.09 0.69 (0.18–2.63) 0.58 1.85 (0.72–4.75) 0.20
AS 56/154 (36%) 1.38 (0.83–2.29) 0.22 1.30 (0.73–2.30) 0.38 1.26 (0.74–2.16) 0.40
ASAQ 164/700 (23%) 1.02 (0.79–1.32) 0.85 0.97 (0.71–1.32) 0.85 1.05 (0.80–1.37) 0.73
ASMQ 257/820 (31%) 0.99 (0.78–1.26) 0.96 1.01 (0.76–1.34) 0.95 1.00 (0.78–1.28) 0.99
ASSP 66/129 (51%) 1.44 (0.85–2.44) 0.17 1.74 (0.94–3.20) 0.08 1.37 (0.79–2.36) 0.27
DP 163/716 (23%) 0.86 (0.67–1.12) 0.26 0.91 (0.68–1.21) 0.51 0.87 (0.67–1.14) 0.31
Q 20/119 (17%) 0.56 (0.31–1.04) 0.07 0.22 (0.05–0.92) 0.04 0.69 (0.32–1.52) 0.36
QC 15/41 (37%) 1.28 (0.51–3.18) 0.60 No data 1.11 (0.37–3.35) 0.86
EGA at malaria episode
4.0–13.9 10/31 (32%) 0.70 (0.31–1.59) 0.39 0.74 (0.30–1.83) 0.51 0.62 (0.27–1.45) 0.27
14.0–19.9 227/765 (30%) Reference Reference Reference
20.0–23.9 246/914 (27%) 0.81 (0.65–1.01) 0.06 0.82 (0.63–1.06) 0.14 0.80 (0.63–1.00) 0.05
24.0–27.9 219/820 (27%) 0.74 (0.59–0.94) 0.01 0.83 (0.63–1.10) 0.20 0.80 (0.63–1.01) 0.07
28.0–36.9 289/1138 (25%) 0.60 (0.48–0.75) < 0.001 0.69 (0.53–0.90) 0.006 0.70 (0.55–0.87) 0.002
≥ 37.0 (weeks) 16/39 (41%) 1.13 (0.56–2.27) 0.74 0.59 (0.15–2.23) 0.43 1.36 (0.66–2.84) 0.41
Age group
< 20 379/1202 (32%) Reference
20–25 332/1185 (28%) 0.65 (0.54–0.79) < 0.001
25–30 170/717 (24%) 0.52 (0.42–0.66) < 0.001
30–35 63/357 (18%) 0.37 (0.27–0.50) < 0.001
≥ 35 (years) 63/246 (26%) 0.55 (0.40–0.77) < 0.001
Pregnancy history
G1 444/1316 (34%) Reference Reference Reference
G2 with no loss 154/614 (25%) 0.58 (0.47–0.73) < 0.001 0.63 (0.49–0.83) < 0.001 0.62 (0.49–0.78) < 0.001
G≥ 3 with no loss 186/1011 (18%) 0.40 (0.33–0.50) < 0.001 0.48 (0.37–0.63) < 0.001 0.48 (0.39–0.60) < 0.001
G2 with 1 loss 76/225 (34%) 0.81 (0.59–1.11) 0.19 0.75 (0.53–1.07) 0.12 0.82 (0.59–1.12) 0.21
G≥ 3 with 1 loss 88/387 (23%) 0.46 (0.35–0.61) < 0.001 0.57 (0.42–0.79) < 0.001 0.54 (0.41–0.72) < 0.001
G≥ 3 with ≥ 2 losses 40/117 (34%) 0.76 (0.50–1.15) 0.19 0.79 (0.47–1.32) 0.37 0.79 (0.51–1.21) 0.27
Weight (kg) 1007/3707 (27%) 0.95 (0.94–0.96) < 0.001
Height (cm) 891/3347 (27%) 0.95 (0.94–0.96) < 0.001 0.95 (0.93–0.96) < 0.001 0.95 (0.93–0.96) < 0.001
BMI (kg/m2) 891/3347 (27%) 0.92 (0.89–0.95) < 0.001 0.92 (0.89–0.96) < 0.001 0.92 (0.89–0.95) < 0.001
HIV infection
Yes 6/24 (25%) 0.92 (0.35–2.42) 0.87 2.45 (0.62–9.73) 0.20 1.04 (0.43–2.55) 0.92
No 849/3105 (27%) Reference Reference Reference
Parasitaemia (log10/μL) 1007/3707 (27%) 1.24 (1.13–1.36) < 0.001 1.20 (1.07–1.35) 0.002 1.14 (1.03–1.26) 0.009
Fever > 37.5 °C
Yes 112/325 (34%) 1.14 (0.88–1.47) 0.33
No 888/3352 (26%) Reference
Haemoglobin (g/dL) 1003/3690 (27%) 0.90 (0.85–0.95) < 0.001
Gametocytaemia
Yes 36/133 (27%) 0.86 (0.57–1.29) 0.45
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pigment in the placenta) were not different following
treatment for patent microscopic falciparum malaria
(uncomplicated or asymptomatic) mainly in the second
or third trimester of pregnancy. The results for the other
treatments (ASSP, AS, AAP, quinine, and QC) need
careful interpretation because of the small number of
women included in the analyses, but generally, they were
associated with similar risks to AL.
The very low proportion of pregnancy loss from mis-
carriage observed in this pooled analysis is a conse-
quence of the natural history of miscarriage, which
decreases considerably after the end of the first trimes-
ter; as the mean gestation at enrolment was > 24.0 weeks,
most participants were already beyond the high risk
period for miscarriage. Therefore, the result of this ana-
lysis does not necessarily reflect the overall impact of
malaria and antimalarial treatment on miscarriage, and
likely underestimates it.
The low proportion of stillbirth (1.7%) in women
treated with highly effective ACTs is notable compared
to a previous systematic review and meta-analysis by
Moore et al., reporting up to 1 in 5 stillbirths attributed
to P. falciparum malaria infection in sub-Saharan Africa
[1]. The included studies in this IPD meta-analysis
screened and detected actively, and treated women for
malaria (and anaemia), which is a higher level of care
than what is usually provided, likely improving outcomes
since early detection, effective treatment, and active
follow-up for at least several weeks are beneficial. The
previous report by Moore et al. [1] was derived predom-
inantly from cross-sectional surveys, retrospective ana-
lysis, or cohort studies, before widespread uptake of
early diagnosis, ACT treatment during pregnancy, and
more reliable EGA measurement.
In this pooled analysis, the prevalence of SGA was
higher than generalized regional estimates reported in
the literature [39]. This higher prevalence of SGA in this
pooled analysis of pregnant women treated for falcip-
arum malaria was likely due to the malaria infection it-
self [3] despite a low proportion of febrile cases on
admission. Furthermore, higher parasite density at base-
line was associated with higher risk of SGA even after
adjusting for gravidity/parity. This highlights the need
for highly effective malaria preventive measures to lower
the risk of SGA. In this study, the risk of SGA was
higher with infection in the early second trimester and
possibly in the late third trimester as was reported previ-
ously [3, 40, 41]. This is compatible with gestational
physiology: development of the placenta is affected by
malaria in early pregnancy [41, 42], and foetal weight
gain increases in the final weeks before delivery [15].
The prevalence of PTB in this pooled analysis was
similar to the general background population [43], sug-
gesting that highly effective antimalarial treatment
alongside improved acute care can lower the immediate
risk of PTB. The rate of febrile symptomatic infections
in this pooled analysis was low which maybe another
reason for relatively low prevalence of PTB. In contrast
to SGA, in the second and third trimester, the risk of
PTB from malaria infection increases towards term as
was shown in an observational cohort study comparing
women with or without malaria infection [3]. Although
there were only a few cases of first trimester malaria in-
fection included in this analysis, the current study sug-
gests that treated malaria infections in the first trimester
are associated with an increased risk of PTB, possibly
mediated by impaired placental development [44].
The prevalence of pigmentation in the placenta in this
pooled analysis was higher than the prevalence reported
in the general population in malaria-endemic areas [45],
which is explained by the fact that all included women
had peripheral malaria detected and treated during preg-
nancy. The pooled proportion of pigment deposition
was 80.1%, a reminder that placental malaria is a proxy
Table 4 Univariable and multivariable logistic regression on the risk of small for gestational age (Continued)
Baseline characteristic Proportion (%) Univariable Multivariable (complete case) Multivariable (MI)
OR (95% CI) p value aOR (95% CI) p value aOR (95% CI) p value
No 953/3522 (27%) Reference
Mixed infection
Yes 14/25 (56%) 3.11 (1.36–7.12) 0.007 1.52 (0.52–4.46) 0.45 2.54 (1.07–5.99) 0.03
No 993/3682 (27%) Reference Reference Reference
Malaria transmission
Low 277/726 (38%) 1.27 (0.80–2.01) 0.32
Moderate 484/2040 (24%) Reference
High 246/941 (26%) 0.94 (0.60–1.47) 0.78
Intraclass correlation, 0.06. AAP artesunate with atovaquone-proguanil, AL artemether-lumefantrine, aOR adjusted odds ratio, AS artesunate monotherapy, ASAQ
artesunate-amodiaquine, ASMQ artesunate-mefloquine, ASSP artesunate-sulfadoxine-pyrimethamine, BMI body mass index, CI confidence interval, DP
dihydroartemisinin-piperaquine, EGA estimated gestational age, G gravidity, HIV human immunodeficiency virus, MI multiple imputation, OR odds ratio, Q quinine
monotherapy, QC quinine with clindamycin
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for malaria in pregnancy. Placental malaria is reported
to be associated with higher risks of LBW and PTB [16,
18–20, 46]. PTB is more likely to be caused by an active
infection at delivery (i.e. acute and chronic infection of
the placenta), whereas previous infection (i.e. past and
chronic infection) is associated with a higher risk of
LBW or IUGR [16, 19, 20]. The risk of placental malaria
is, in turn, affected by gravidity, age, number of malaria
infections, and parasite density [16, 47], which was
confirmed in this IPD meta-analysis (with the exception
of frequency of parasitaemia, which could not be
assessed). Additionally, a higher risk of placental malaria
was observed in women with higher body temperature
before treatment, which can be a surrogate for the sever-
ity of the infection; inflammatory cytokines causing fever
(e.g. TNF-α) are reported to be associated with a higher
parasite burden in the placenta [16, 48]. The presence of
gametocytes at baseline and lower haemoglobin can
Table 5 Univariable and multivariable logistic regression on the risk of malaria pigment deposition in the placenta
Baseline characteristic Proportion (%) Univariable Multivariable
OR (95% CI) p value aOR (95% CI) p value
Treatment
AL 733/880 (83%) Reference Reference
AS 56/84 (67%) 1.63 (0.86–3.10) 0.13 1.77 (0.85–3.68) 0.13
ASAQ 544/645 (84%) 0.93 (0.67–1.29) 0.68 0.90 (0.63–1.28) 0.55
ASMQ 560/658 (85%) 0.80 (0.57–1.12) 0.20 0.78 (0.54–1.13) 0.20
DP 559/642 (87%) 0.96 (0.67–1.36) 0.81 0.91 (0.62–1.34) 0.64
Q 53/78 (68%) 1.05 (0.55–2.00) 0.89 0.80 (0.38–1.66) 0.55
Interval from malaria to delivery (week) 2505/2987 (84%) 0.98 (0.96–0.99) 0.005 0.97 (0.95–0.99) 0.002
Age (year) 2505/2987 (84%) 0.89 (0.88–0.91) < 0.001 0.93 (0.91–0.95) < 0.001
Parity
0 1199/1292 (93%) Reference Reference
1 498/580 (86%) 0.50 (0.36–0.69) < 0.001 0.82 (0.58–1.17) 0.27
≥ 2 807/1112 (73%) 0.21 (0.16–0.27) < 0.001 0.59 (0.41–0.86) 0.006
Weight (kg) 2505/2987 (84%) 0.97 (0.96–0.98) < 0.001
Height (cm) 2383/2806 (85%) 0.98 (0.96–1.00) 0.01
BMI (kg/m2) 2383/2806 (85%) 0.95 (0.92–0.99) 0.008
HIV infection
Yes 18/24 (75%) 1.06 (0.40–2.82) 0.91
No 2035/2414 (84%) Reference
Parasitaemia (log10/μL) 2505/2987 (84%) 2.04 (1.76–2.35) < 0.001 1.67 (1.42–1.96) < 0.001
Body temperature (°C) 2504/2986 (84%) 1.35 (1.13–1.61) < 0.001 1.22 (1.00–1.49) 0.045
Haemoglobin (g/dL) 2500/2978 (84%) 0.65 (0.60–0.70) < 0.001 0.72 (0.65–0.78) < 0.001
Gametocytaemia
Yes 84/91 (92%) 3.60 (1.62–7.97) 0.002 3.62 (1.58–8.26) 0.002
No 2417/2891 (84%) Reference Reference
Mixed infection
Yes 12/16 (75%) 1.82 (0.57–5.82) 0.31
No 2493/2971 (84%) Reference
Malaria transmission
Low 159/249 (64%) 1.16 (0.57–2.34) 0.69 0.81 (0.34–1.91) 0.63
Moderate 1588/1838 (86%) Reference Reference
High 758/900 (84%) 1.14 (0.66–1.96) 0.65 1.16 (0.63–2.13) 0.64
Intraclass correlation, 0.14. AL artemether-lumefantrine, aOR adjusted odds ratio, AS artesunate monotherapy, ASAQ artesunate-amodiaquine, ASMQ artesunate-
mefloquine, BMI body mass index, CI confidence interval, DP dihydroartemisinin-piperaquine, EGA estimated gestational age, G gravidity, HIV human
immunodeficiency virus, OR odds ratio, Q quinine monotherapy
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reflect a more extended period of infection before treat-
ment [49, 50], although haemoglobin in pregnancy can
be affected by gestational age or provision of supple-
ments at antenatal care. A longer interval between the
treated malaria episode and delivery was associated with
a lower risk of placental malaria, which has also been
shown in previous studies [46, 51–53]. These results
may support an earlier finding from a low transmission
area that malaria pigment in the placenta can be cleared
over time after prompt and effective treatment or that
early detection and treatment prevents pigment deposit-
ing in the placenta [53–56].
There are several strengths of this meta-analysis. Pri-
marily, use of IPD, collected in prospective trials in
which gestational age was predominantly assessed by
ultrasound, allowed analysis of the largest number of
pregnant women ever to be assembled to assess the im-
pact of different treatments by the gestation age of fal-
ciparum malaria infection in pregnancy. With no
registered trials currently recruiting pregnant women for
assessment of efficacy of antimalarial treatment in preg-
nancy [23], it is unlikely that a larger dataset will be
available in the foreseeable future. Gestational age was
strictly defined and assessed with ultrasound for > 90%
of women included. Individual studies used different
cut-offs or definitions [11]; thus, aggregated data meta-
analysis was difficult. With IPD, standardized definitions
for both exposures and outcomes were applied. SGA
was assessed using the same standard growth chart, and
the use of SGA, rather than LBW or birthweight, is pref-
erable as it is a more reliable indicator of foetal growth.
Some limitations of this study should be considered.
Though confounders for each study were assessed (e.g.
age, height, BMI, parity or gravidity, HIV status) and ad-
justed in our IPD meta-analyses, it is possible that some
potential confounders remained unadjusted. For ex-
ample, the number of malaria episodes during pregnancy
was reported to be cumulatively associated with an in-
creased risk of SGA [3, 5] or placental malaria [46]. The
use of insecticide-treated bed nets and the history of
malaria and antimalarial use including IPTp before and
after the study period were not always available (or not
systematically collected). As IPTp is associated with a
lower risk of LBW [57], it is possible that we have
underestimated the impact of malaria on the pregnancy
outcomes by missing some unreported IPTp interven-
tion [11]. However, these two preventive measures can
be regarded as an unmeasured study-level information
and was statistically taken into account by mixed-effects
model. Most of the women included in this pooled ana-
lysis were not febrile and had relatively low parasitaemia,
and this might be used to explain the lack of a difference
between highly efficacious antimalarial treatments. This
characteristic is, however, more likely to underestimate
the adverse impact by malaria. The high risk of SGA
after treated malaria in this pooled analysis is profound
and supports a policy of prevention but also promotes
the use of early detection by screening and treatment of
parasitaemia regardless of symptoms for pregnancy. Pre-
vious systematic reviews concluded that malaria in preg-
nancy is associated with increased risk of stillbirth,
LBW, and PTB compared with those without malaria [1,
4]. The current study, including only malaria treatment
episodes, compared the impact of different treatments,
and we have additionally compared them with the most
recent regional estimates. Although it was not possible
to assess the risks of outcomes without treatment, with
what we now know about the harmful effects of malaria,
such a study would clearly be unethical. Similarly, the
first documented diagnosis of malaria does not exclude
previous malaria episodes: included women may have
had malaria before study enrolment, and late study en-
rolment might mean antenatal care attendance started in
later gestation.
Multiple factors, including obstetric history, morbidity
such as hypertensive disorders of pregnancy, gestational
diabetes, sub-optimal gestational weight gain, and peri-
natal depression, and social factors, including employ-
ment, smoking, marital status, and literacy, can all be
associated with pregnancy outcomes [43, 58–62], but
this information was not available in most studies [11].
The previous history of pregnancy loss (stillbirth and
miscarriage) was only roughly estimated by parity and
gravidity in this meta-analysis. BMI was assessed using
body weight at enrolment rather than pre-pregnancy
weight. For comparability of outcomes to previous stud-
ies, infants with congenital abnormality and twins were
excluded from our analyses. This exclusion would
underestimate the true burden of stillbirth, PTB, and
SGA and may reduce the effect size of comparisons but
not the direction of associations. The number of twins
and congenital abnormalities was small and did not dif-
fer by antimalarial treatment. As less than 1% of the
pregnant women included in this analysis were enrolled
and treated in the first trimester, the risk of congenital
abnormality due to antimalarial drugs is expected to be
very low in the current study. Congenital abnormalities
in stillborns were presumably underreported, but aut-
opsy or chromosomal investigation was not mentioned
in any of the study sites [63, 64]. Due to the availability
of information, placental pigmentation was analysed only
qualitatively, while a previous study revealed AL reduced
the level of pigmentation more than quinine [53]. Quan-
titative analysis can be a better way to assess the impact
of different treatments, particularly regarding the clear-
ance (rather than prevalence) of placental malaria. Anti-
malarial resistance can affect the response to treatment
in terms of efficacy which impacts pregnancy outcomes,
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and needs to be addressed in the future, considering in
particular the expansion of artemisinin resistance.
Although the use of artemisinin derivatives in the first
trimester seems to be safe [2, 65], the small number of
pregnant women available in this analysis is not suffi-
cient to compare the safety profile of the different ACTs
in the first trimester. The risk of PTB following malaria
infection in the first trimester can be higher than infec-
tion in later gestational period, indicating that preven-
tion measures should start early in pregnancy. Evidence
on the efficacy and safety of ACT treatment in the first
trimester, either as treatment or prevention, is thus
needed.
Conclusions
This IPD meta-analysis of over 4500 women infected
with falciparum malaria from both Asia and sub-
Saharan Africa demonstrated that the risks of late mis-
carriage and stillbirth were low, and late miscarriage,
stillbirth, PTB, SGA, and placental malaria were not dif-
ferent between the most commonly used ACTs (i.e. AL,
ASAQ, ASMQ, and DP) in the second and third trimes-
ters. Accurate assessment of EGA, malaria episodes be-
yond the current study framework (28–63 days), and
thorough reporting of congenital abnormality, including
abnormality in stillbirth, should be considered in future
studies. Early diagnosis of parasitaemia, regardless of
symptoms, and treatment with highly effective ACTs
may result in improved pregnancy outcomes, but highly
effective preventive measures are required to reduce the
high rate of SGA.
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